Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
143.2 USD | -1.14% | +0.71% | +13.68% |
Sales 2024 * | 425M 455M | Sales 2025 * | 742M 796M | Capitalization | 7.65B 8.21B |
---|---|---|---|---|---|
Net income 2024 * | -236M -253M | Net income 2025 * | 10M 10.72M | EV / Sales 2024 * | 18.9 x |
Net Debt 2024 * | 390M 418M | Net Debt 2025 * | 323M 346M | EV / Sales 2025 * | 10.7 x |
P/E ratio 2024 * |
-31.2
x | P/E ratio 2025 * |
3,202
x | Employees | 879 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 10.4% |
Latest transcript on Ascendis Pharma A/S
1 day | -1.14% | ||
1 week | +0.71% | ||
Current month | -5.29% | ||
1 month | -1.27% | ||
3 months | +6.76% | ||
6 months | +62.61% | ||
Current year | +13.68% |
Managers | Title | Age | Since |
---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Scott Smith
DFI | Director of Finance/CFO | 50 | 16-08-07 |
Stina Singel
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Albert Cha
CHM | Chairman | 51 | 14-10-31 |
General Counsel | 53 | 07-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.96% | 11 M€ | -6.03% | - | |
0.48% | 0 M€ | 0.00% | - | |
0.45% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 143.2 | -1.14% | 244,224 |
24-04-23 | 144.8 | +1.92% | 220,120 |
24-04-22 | 142.1 | +1.38% | 245,698 |
24-04-19 | 140.2 | -0.51% | 280,701 |
24-04-18 | 140.9 | -0.90% | 222,169 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.68% | 8.18B | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.57% | 22.2B | |
-16.53% | 21.23B | |
-8.49% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- ASND Stock